BIIB vs VRTX
Biogen vs Vertex Pharmaceuticals — AI-powered side-by-side comparison
VS
VRTX
Vertex Pharmaceuticals
67
Buy
| Metric | BIIB | VRTX |
|---|
| AI Score |
67
|
67
|
| Price |
$208.02
|
$496.21
|
| P/E Ratio |
36.61×
|
28.64×
|
| ROE |
7.1%
|
21.2%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
67.7%
|
86.0%
|
| Debt / Equity |
0.44×
|
0.00×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
56.7
|
66.6
|
| Beta |
0.158
|
0.292
|
| Expected Upside |
+5.2%
|
+2.3%
|
AI Committee View
Current Innellis committee reasoning for BIIB versus VRTX.
The committee scores are tied.
BIIB and VRTX both score 67/100.
BIIB Committee View
80% agreement
5 analysts
The primary driver is news sentiment is positive (+0.42 across 47 articles, 14d). The main limiting factor is growth rate is decelerating quarter over quarter -- the trend line matters more than the level. The committee is constructive but not yet at full conviction.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
VRTX Committee View
67% agreement
6 analysts
The primary driver is low leverage (debt-to-equity 0.01) -- balance sheet can absorb a shock. The main limiting factor is p/e of 28.3 is moderate-to-rich. The committee is constructive but not yet at full conviction.
Bull Case
- ROE of 23.3% shows genuine earnings power backing the valuation — Value
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- P/E of 28.3 is moderate-to-rich — Value
- Price-to-book of 6.2x prices in significant intangible value — Value
- Price trading above the upper Bollinger Band -- stretched — Technical